Fujifilm Medical Systems USA and Dutch artificial intelligence (AI) software developer ScreenPoint Medical are partnering on AI for breast cancer detection.
The two firms will incorporate ScreenPoint Medical's Transpara fusion AI for 2D and 3D mammography software with Fujifilm's Aspire Cristalle mammography system with digital breast tomosynthesis (DBT).
Transpara includes the following applications:
- Transpara Perception Aid, which marks findings directly for review
- Transpara Decision Support, which allows radiologists to investigate suspicious regions while reading mammograms
- Transpara Score, which categorizes mammograms in ten equally sized groups to predict malignancy
The U.S. Food and Drug Administration (FDA) cleared the software in 2020.
